search

Active clinical trials for "Carcinoma, Renal Cell"

Results 1181-1190 of 1644

Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer

Recurrent Renal Cell Cancer

This randomized pilot trial studies clamped or unclamped surgery in treating patients with kidney cancer. Unclamped surgery for kidney cancer may have fewer side effects

Terminated18 enrollment criteria

INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised...

Metastatic Renal Cell Carcinoma

This study aims to report the effects of immediate or delayed exercise training on patients with advanced or metastatic renal cell carcinoma who are receiving nivolumab and ipilimumab.

Terminated27 enrollment criteria

Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With...

Metastatic Renal Cell Carcinoma Treated With Cabozantinib

The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.

Terminated3 enrollment criteria

Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated...

Metastatic Renal Cell Carcinoma

Multicenter, randomized, open-label, 2-arm, parallel-group, phase III study whose goal is to assess the efficacy and safety profile of bone-targeted treatments (Arm A: denosumab or zoledronic acid) versus the control arm (Arm B: no specific treatment) in patients with bone metastases under targeted therapy for Metastatic Renal Cell Carcinoma.

Terminated25 enrollment criteria

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

Renal Cell CarcinomaUrothelial Carcinoma

The purpose of this research is to collect health-related information as well as bone marrow and blood specimens to determine if a new form of treatment for patients with kidney and bladder cancer may be possible.

Terminated20 enrollment criteria

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

CarcinomaRenal Cell

The purpose of this study is to: To elucidate the mechanism involved in the sorafenib-induced hypophosphatemia and possible early effect of hypophosphatemia on bone mineral density A secondary objective to assess the effect sorafenib treatment on evaluate left ventricular function (LVEF) and Beta-type natriuretic peptide in plasma.

Terminated41 enrollment criteria

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A...

Advanced Solid TumorCDKN2A8 more

This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed homozygous CDKN2A loss and WT TP53 who have progressed on or are refractory to prior PD-1/PD-L1 inhibitor therapy and who, in the opinion of the Investigator, are unlikely to tolerate or derive clinically meaningful benefit from other therapy. This study will determine the recommended dose of milademetan when given in combination with atezolizumab (the combination RP2D) using a dose de-escalation safety assessment cohort (Phase 1b). Following identification of the combination RP2D, the safety profile and preliminary anti-tumor activity of the combination RP2D will be evaluated in a larger population in a dose expansion cohort (Phase 2).

Withdrawn20 enrollment criteria

A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer

Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma

This pilot clinical trial studies the side effects of stereotactic body radiation therapy and pazopanib hydrochloride in treating patients with kidney cancer who are not able to undergo surgery. Stereotactic body radiation therapy is a specialized radiation therapy that delivers high doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Pazopanib hydrochloride may stop the growth of tumor cells by blocking an enzyme needed for cell growth. Giving pazopanib hydrochloride before stereotactic body radiation therapy may help make the tumor smaller and be an alternative treatment for patients who cannot undergo surgery.

Withdrawn35 enrollment criteria

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Clear Cell Renal Carcinoma

The study is designed to explore the safety and tolerability as well as diagnostic 89Zr-girentuximab for imaging CCRC by PET/CT. This study does not offer any treatment for patients with CCRC; therefore, patients will be offered state of the art therapeutic options after imaging with the study drug 89Zr-girentuximab. Cancer treatment will not be delayed by study participation.

Completed16 enrollment criteria

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer...

Clear Cell Papillary Renal NeoplasmCollecting Duct Carcinoma9 more

This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.

Withdrawn47 enrollment criteria
1...118119120...165

Need Help? Contact our team!


We'll reach out to this number within 24 hrs